Joint telehealth development to assist in diagnosing respiratory disease

Joint telehealth development to assist in diagnosing respiratory disease

Two digital health companies have joined forces to expand access to telehealth services targeted specifically at diagnosing respiratory diseases.

ResApp Health (ASX: RAP) will integrate its acute respiratory diagnostic test ResAppDx-EU into Phenix Health's telehealth smartphone app.

The partnership is a significant step toward accelerating diagnosis and treatment of respiratory diseases considering users of Phenix Health's app no longer have to rely on additional hardware; diagnosis can occur entirely within a single telehealth session.

By using machine learning algorithms, ResAppDx-EU analyses patients' cough sounds to diagnose lower respiratory tract diseases such as pneumonia and asthma exacerbations.

Ultimately, the partnership will enable doctors to determine whether a patient should attend a hospital or clinic for additional care, thus conserving already strained healthcare resources.

With people around the world encouraged to remain at home as much as possible telehealth technology is becoming a vital tool to help slow the spread of the novel coronavirus, enabling sick patients to see a doctor at a distance, away from those most vulnerable in the broader community.


Global Health answers call for virtual GP sessions


According to CEO and founder of Phenix Health Dr Gillian Alexis the company's app is well positioned to provide a valuable service to the Australian community.

"Phenix provides video consultations to patients across Australia and, since the beginning of this crisis, we have seen a 30 per cent month-on-month increase in the number of consultations," says Alexis.

"Our virtual clinic can be accessed nationwide through HealthEngine or directly via our downloadable app, and for patients told to self-isolate for possible COVID-19, these consultations are reimbursable under the MBS scheme."

"Phenix knows that implementing a telehealth service for patients must go beyond the limits of consumer video chat platforms like Skype which is why we are working with ResApp to bring their advanced diagnostic tool to our platform."

Shares in ResApp are up 117.39 per cent to $0.15 per share at 3:11PM AEDT.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Get our daily business news

Sign up to our free email news updates.

 
Finexia’s Childcare Income Fund secures ‘very strong’ rating from Foresight Analytics & Ratings
Partner Content
Private credit specialist Finexia Financial Group (ASX: FNX) has secured a “very...
Finexia
Advertisement

Related Stories

‘Toxic culture’: Whistleblower’s complaint hangs over The Star’s former CEO

‘Toxic culture’: Whistleblower’s complaint hangs over The Star’s former CEO

Robbie Cooke, the former CEO of The Star Entertainment Group (ASX: ...

Japanese investment in Australia hit record high of $133.8 billion in 2023

Japanese investment in Australia hit record high of $133.8 billion in 2023

Japanese finance has been described as one of the "great untol...

Melbourne-based diversity data analytics platform raises $6 million

Melbourne-based diversity data analytics platform raises $6 million

In response to "unprecedented demand" for its propri...

Tasmanian sustainability accounting startup Sumday raises $5.3m

Tasmanian sustainability accounting startup Sumday raises $5.3m

"The future of accounting includes carbon" is the message...